Evidence map›Paper›PMID 27835899›Full record

ArticleOncotarget2016

Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Marcus Franz, Katja Grün, Stefan Betge, Ilonka Rohm, Bernadin Ndongson-Dongmo, Reinhard Bauer, P Christian Schulze, Michael Lichtenauer, Iver Petersen, Dario Neri and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension.International journal of molecular sciences · 2017
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Marcus FranzDepartment of Internal Medicine I, Jena University Hospital, Jena, Germany.
Katja GrünDepartment of Internal Medicine I, Jena University Hospital, Jena, Germany.
Stefan BetgeDepartment of Angiology, Cardiovascular Center Bad Bevensen, Bad Bevensen, Germany.
Ilonka RohmDepartment of Internal Medicine I, Jena University Hospital, Jena, Germany.
Bernadin Ndongson-DongmoInstitute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
Reinhard BauerInstitute of Molecular Cell Biology, Center for Molecular Biomedicine, Jena University Hospital, Jena, Germany.
P Christian SchulzeDepartment of Internal Medicine I, Jena University Hospital, Jena, Germany.
Michael LichtenauerClinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria.
Iver PetersenInstitute of Pathology, Jena University Hospital, Jena, Germany.
Dario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland.
Alexander BerndtInstitute of Pathology, Jena University Hospital, Jena, Germany.
Christian JungDepartment of Internal Medicine, Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University, Düsseldorf, Germany.
Jena University Hospital · DEETH Zurich · CHHeinrich Heine University Düsseldorf · DEParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) is associated with vasoconstriction and remodelling. We studied lung tissue remodelling in a rat model of PH with special focus on histology and extracellular matrix (ECM) remodelling. After induction of PH by monocrotaline, lung tissue was analysed histologically, by gene expression analysis and immunofluorescence labelling of ED-A domain containing fibronectin (ED-A+ Fn), B domain containing tenascin-C (B+ Tn-C) as well as alpha-smooth muscle actin (α-SMA). Serum concentrations of ED-A+ Fn were determined by ELISA. Systolic right ventricular pressure (RVPsys) values were significantly elevated in PH (n = 18; 75 ± 26.4 mmHg) compared to controls (n = 10; 29 ± 19.3 mmHg; p = 0.015). The histological sum-score was significantly increased in PH (8.0 ± 2.2) compared to controls (2.5 ± 1.6; p < 0.001). Gene expression analysis revealed relevant induction of several key genes of extracellular matrix remodelling. Increased protein deposition of ED-A+ Fn but not of B+ Tn-C and α-SMA in lung tissue was found in PH (2.88 ± 3.19 area%) compared to controls (1.32 ± 0.16 area%; p = 0.030). Serum levels of ED-A+ Fn were significantly higher in PH (p = 0.007) positively correlating with RVPsys (r = 0.618, p = 0.019). We here present a novel histological scoring system to assess lung tissue remodelling in PH. Gene expression analysis revealed induction of candidate genes involved in collagen matrix turnover, fibrosis and vascular remodelling. The stable increased tissue deposition of ED-A+ Fn in PH as well as its dynamics in serum suggests a role as a promising novel biomarker and potential therapeutic target.

Indexed as

MonocrotalineActinsAnimalsDisease Models, AnimalExtracellular MatrixExtracellular Matrix ProteinsFibronectinsFibrosisGene Expression ProfilingGene Expression RegulationHemodynamicsHypertension, PulmonaryLungOligonucleotide Array Sequence AnalysisRats, Sprague-DawleySeverity of Illness IndexActa2 protein, ratActinsExtracellular Matrix ProteinsFibronectinsMonocrotalineTenascinextracellular matrixfibronectinhistological scorepulmonary hypertensionremodeling

Identifiers

PMID27835899
PMCPMC5348389
OpenAlexW2549969123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.